Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An international tamoxifen exemestane adjuvant multinational trial analysis

Research output: Contribution to journalArticlepeer-review

Standard

Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors : An international tamoxifen exemestane adjuvant multinational trial analysis. / Fontein, Duveken B.Y.; Seynaeve, Caroline; Hadji, Peyman; Hille, Elysée T.M.; Van De Water, Willemien; Putter, Hein; Kranenbarg, Elma Meershoek Klein; Hasenburg, Annette; Paridaens, Robert J.; Vannetzel, Jean Michel; Markopoulos, Christos; Hozumi, Yasuo; Bartlett, John M.S.; Jones, Stephen E.; Rea, Daniel William; Nortier, Johan W.R.; Van De Velde, Cornelis J.H.

In: Journal of Clinical Oncology, Vol. 31, No. 18, 20.06.2013, p. 2257-2264.

Research output: Contribution to journalArticlepeer-review

Harvard

Fontein, DBY, Seynaeve, C, Hadji, P, Hille, ETM, Van De Water, W, Putter, H, Kranenbarg, EMK, Hasenburg, A, Paridaens, RJ, Vannetzel, JM, Markopoulos, C, Hozumi, Y, Bartlett, JMS, Jones, SE, Rea, DW, Nortier, JWR & Van De Velde, CJH 2013, 'Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An international tamoxifen exemestane adjuvant multinational trial analysis', Journal of Clinical Oncology, vol. 31, no. 18, pp. 2257-2264. https://doi.org/10.1200/JCO.2012.45.3068

APA

Fontein, D. B. Y., Seynaeve, C., Hadji, P., Hille, E. T. M., Van De Water, W., Putter, H., Kranenbarg, E. M. K., Hasenburg, A., Paridaens, R. J., Vannetzel, J. M., Markopoulos, C., Hozumi, Y., Bartlett, J. M. S., Jones, S. E., Rea, D. W., Nortier, J. W. R., & Van De Velde, C. J. H. (2013). Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An international tamoxifen exemestane adjuvant multinational trial analysis. Journal of Clinical Oncology, 31(18), 2257-2264. https://doi.org/10.1200/JCO.2012.45.3068

Vancouver

Author

Fontein, Duveken B.Y. ; Seynaeve, Caroline ; Hadji, Peyman ; Hille, Elysée T.M. ; Van De Water, Willemien ; Putter, Hein ; Kranenbarg, Elma Meershoek Klein ; Hasenburg, Annette ; Paridaens, Robert J. ; Vannetzel, Jean Michel ; Markopoulos, Christos ; Hozumi, Yasuo ; Bartlett, John M.S. ; Jones, Stephen E. ; Rea, Daniel William ; Nortier, Johan W.R. ; Van De Velde, Cornelis J.H. / Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors : An international tamoxifen exemestane adjuvant multinational trial analysis. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 18. pp. 2257-2264.

Bibtex

@article{6e3e9692086c4d0bbee78043cec1188b,
title = "Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An international tamoxifen exemestane adjuvant multinational trial analysis",
abstract = "Purpose: Specific adverse events (AEs) associated with endocrine therapy and related to depletion or blocking of circulating estrogens may be related to treatment efficacy. We investigated the relationship between survival outcomes and specific AEs including vasomotor symptoms (VMSs), musculoskeletal adverse events (MSAEs), and vulvovaginal symptoms (VVSs) in postmenopausal patients with breast cancer participating in the international Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Patients and Methods: Primary efficacy end points were disease-free survival (DFS), overall survival (OS), and distant metastases (DM). VMSs, MSAEs, and VVSs arising in the first year of endocrine treatment were considered. Patients who did not start or who discontinued their allocated therapy and/or had an event (recurrence/death) within 1 year after randomization were excluded. Landmark analyses and time-dependent multivariate Cox proportional hazards models assessed survival differences up to 5 years from the start of treatment. Results: A total of 9,325 patients were included. Patients with specific AEs (v nonspecific or no AEs) had better DFS and OS (multivariate hazard ratio [HR] for DFS: VMSs, 0.731 [95% CI, 0.618 to 0.866]; MSAEs, 0.826 [95% CI, 0.694 to 0.982]; VVSs, 0.769 [95% CI, 0.585 to 1.01]; multivariate HR for OS: VMSs, 0.583 [95% CI, 0.424 to 0.803]; MSAEs, 0.811 [95% CI, 0.654 to 1.005]; VVSs, 0.570 [95% CI, 0.391 to 0.831]) and fewer DM (VMSs, 0.813 [95% CI, 0.664 to 0.996]; MSAEs, 0.749 [95% CI, 0.601 to 0.934]; VVSs, 0.687 [95% CI, 0.436 to 1.085]) than patients not reporting these symptoms. Increasing numbers of specific AEs were also associated with better survival outcomes. Outcomes were unrelated to treatment allocation. Conclusion: Certain specific AEs are associated with superior survival outcomes and may therefore be useful in predicting treatment responses in patients with breast cancer treated with endocrine therapy.",
author = "Fontein, {Duveken B.Y.} and Caroline Seynaeve and Peyman Hadji and Hille, {Elys{\'e}e T.M.} and {Van De Water}, Willemien and Hein Putter and Kranenbarg, {Elma Meershoek Klein} and Annette Hasenburg and Paridaens, {Robert J.} and Vannetzel, {Jean Michel} and Christos Markopoulos and Yasuo Hozumi and Bartlett, {John M.S.} and Jones, {Stephen E.} and Rea, {Daniel William} and Nortier, {Johan W.R.} and {Van De Velde}, {Cornelis J.H.}",
year = "2013",
month = jun,
day = "20",
doi = "10.1200/JCO.2012.45.3068",
language = "English",
volume = "31",
pages = "2257--2264",
journal = "Journal of Clinical Oncology ",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "18",

}

RIS

TY - JOUR

T1 - Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors

T2 - An international tamoxifen exemestane adjuvant multinational trial analysis

AU - Fontein, Duveken B.Y.

AU - Seynaeve, Caroline

AU - Hadji, Peyman

AU - Hille, Elysée T.M.

AU - Van De Water, Willemien

AU - Putter, Hein

AU - Kranenbarg, Elma Meershoek Klein

AU - Hasenburg, Annette

AU - Paridaens, Robert J.

AU - Vannetzel, Jean Michel

AU - Markopoulos, Christos

AU - Hozumi, Yasuo

AU - Bartlett, John M.S.

AU - Jones, Stephen E.

AU - Rea, Daniel William

AU - Nortier, Johan W.R.

AU - Van De Velde, Cornelis J.H.

PY - 2013/6/20

Y1 - 2013/6/20

N2 - Purpose: Specific adverse events (AEs) associated with endocrine therapy and related to depletion or blocking of circulating estrogens may be related to treatment efficacy. We investigated the relationship between survival outcomes and specific AEs including vasomotor symptoms (VMSs), musculoskeletal adverse events (MSAEs), and vulvovaginal symptoms (VVSs) in postmenopausal patients with breast cancer participating in the international Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Patients and Methods: Primary efficacy end points were disease-free survival (DFS), overall survival (OS), and distant metastases (DM). VMSs, MSAEs, and VVSs arising in the first year of endocrine treatment were considered. Patients who did not start or who discontinued their allocated therapy and/or had an event (recurrence/death) within 1 year after randomization were excluded. Landmark analyses and time-dependent multivariate Cox proportional hazards models assessed survival differences up to 5 years from the start of treatment. Results: A total of 9,325 patients were included. Patients with specific AEs (v nonspecific or no AEs) had better DFS and OS (multivariate hazard ratio [HR] for DFS: VMSs, 0.731 [95% CI, 0.618 to 0.866]; MSAEs, 0.826 [95% CI, 0.694 to 0.982]; VVSs, 0.769 [95% CI, 0.585 to 1.01]; multivariate HR for OS: VMSs, 0.583 [95% CI, 0.424 to 0.803]; MSAEs, 0.811 [95% CI, 0.654 to 1.005]; VVSs, 0.570 [95% CI, 0.391 to 0.831]) and fewer DM (VMSs, 0.813 [95% CI, 0.664 to 0.996]; MSAEs, 0.749 [95% CI, 0.601 to 0.934]; VVSs, 0.687 [95% CI, 0.436 to 1.085]) than patients not reporting these symptoms. Increasing numbers of specific AEs were also associated with better survival outcomes. Outcomes were unrelated to treatment allocation. Conclusion: Certain specific AEs are associated with superior survival outcomes and may therefore be useful in predicting treatment responses in patients with breast cancer treated with endocrine therapy.

AB - Purpose: Specific adverse events (AEs) associated with endocrine therapy and related to depletion or blocking of circulating estrogens may be related to treatment efficacy. We investigated the relationship between survival outcomes and specific AEs including vasomotor symptoms (VMSs), musculoskeletal adverse events (MSAEs), and vulvovaginal symptoms (VVSs) in postmenopausal patients with breast cancer participating in the international Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Patients and Methods: Primary efficacy end points were disease-free survival (DFS), overall survival (OS), and distant metastases (DM). VMSs, MSAEs, and VVSs arising in the first year of endocrine treatment were considered. Patients who did not start or who discontinued their allocated therapy and/or had an event (recurrence/death) within 1 year after randomization were excluded. Landmark analyses and time-dependent multivariate Cox proportional hazards models assessed survival differences up to 5 years from the start of treatment. Results: A total of 9,325 patients were included. Patients with specific AEs (v nonspecific or no AEs) had better DFS and OS (multivariate hazard ratio [HR] for DFS: VMSs, 0.731 [95% CI, 0.618 to 0.866]; MSAEs, 0.826 [95% CI, 0.694 to 0.982]; VVSs, 0.769 [95% CI, 0.585 to 1.01]; multivariate HR for OS: VMSs, 0.583 [95% CI, 0.424 to 0.803]; MSAEs, 0.811 [95% CI, 0.654 to 1.005]; VVSs, 0.570 [95% CI, 0.391 to 0.831]) and fewer DM (VMSs, 0.813 [95% CI, 0.664 to 0.996]; MSAEs, 0.749 [95% CI, 0.601 to 0.934]; VVSs, 0.687 [95% CI, 0.436 to 1.085]) than patients not reporting these symptoms. Increasing numbers of specific AEs were also associated with better survival outcomes. Outcomes were unrelated to treatment allocation. Conclusion: Certain specific AEs are associated with superior survival outcomes and may therefore be useful in predicting treatment responses in patients with breast cancer treated with endocrine therapy.

UR - http://www.scopus.com/inward/record.url?scp=84883047727&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.45.3068

DO - 10.1200/JCO.2012.45.3068

M3 - Article

C2 - 23610112

AN - SCOPUS:84883047727

VL - 31

SP - 2257

EP - 2264

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 18

ER -